Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 12/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442838 | 0.92 | CYP11B2 (0.40) | MDM2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL5432191 | 0.89 | KCNH2 (0.41) | MDM2NPC1RAB9ASMN1; SMN2BCHE | |
| SCHEMBL5397669 | 0.89 | HCRTR1 (0.40) | NPC1RAB9ASMN1; SMN2BCHETP53 | |
| SCHEMBL5406644 | 0.81 | NPC1 (0.39) | MDM2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL5397680 | 0.80 | CYP11B2 (0.42) | NPC1RAB9ASMN1; SMN2TP53THRB | |
| SCHEMBL5432422 | 0.80 | GRM2 (0.40) | MDM2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4347443 | 0.79 | NPC1 (0.38) | MDM2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4347449 | 0.79 | NPC1 (0.38) | MDM2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL5433709 | 0.78 | KCNH2 (0.42) | NPC1RAB9ASMN1; SMN2BCHETP53 | |
| SCHEMBL5450497 | 0.78 | KCNH2 (0.42) | NPC1RAB9ASMN1; SMN2BCHETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007523181-A | — | — | 2007-08-16 | — | — | JP | claimed |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | claimed |
| EP-1716143-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | claimed |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-02-02 | — | — | US | claimed |
| WO-2005080386-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | claimed |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1716143-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-02-02 | — | — | US | disclosed |
| WO-2005080386-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | MDM2 4268/4885NPC1 2424/4885RAB9A 3419/4885 |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | MDM2 4376/4885NPC1 2449/4885RAB9A 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.